

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Proposed Single Technology Appraisal**

**Lumacaftor in combination with ivacaftor for treating cystic fibrosis homozygous for the F508del mutation [ID786]**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Vertex Pharmaceuticals (lumacaftor, ivacaftor)</li> </ul> <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> <li>• Action for Sick Children</li> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• British Lung Foundation</li> <li>• Contact a Family</li> <li>• Cystic Fibrosis Trust</li> <li>• Equalities National Council</li> <li>• Genetic Alliance</li> <li>• Jewish Genetic Disorders UK</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• National Children's Bureau</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Together for Short Lives</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses and Counsellors</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• British Paediatric Respiratory Society</li> <li>• British Thoracic Society</li> <li>• British Society for Genetic Medicine</li> <li>• Chartered Society of Physiotherapists</li> <li>• Primary Care Respiratory Society UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics &amp; Child Health</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Abbott Healthcare (pancreatin)</li> <li>• Actavis (carbocisteine)</li> <li>• Arrow (carbocisteine)</li> <li>• Essential Pharmaceuticals (pancreatin)</li> <li>• Forest Laboratories (nebulised hypertonic sodium chloride)</li> <li>• Janssen (pancreatin)</li> <li>• Merck Serono (pancreatin)</li> <li>• Pari Medical (nebulised hypertonic sodium chloride)</li> <li>• Pharmaxis (mannitol dry powder for inhalation)Roche Products (dornase alfa)</li> <li>• Sanofi (carbocisteine)</li> <li>• Teva (carbocisteine)</li> <li>• Zentiva (carbocisteine)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Genetic Testing Network</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Newark &amp; Sherwood CCG</li> <li>• NHS West Leicestershire CCG</li> <li>• Welsh Government</li> </ul>	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Association for Lung Research</li> <li>• CF Unite</li> <li>• Cochrane Cystic Fibrosis and Genetic Disorders Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• UK Cystic Fibrosis Gene Therapy Consortium</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that markets comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.